On June 1, 2026, Anticancer Research issued an Expression of Concern regarding Hulscher et al.’s study on ivermectin-mebendazole, citing issues with data verifiability, statistical reliability, and ethical oversight. The study’s self-reported outcomes and lack of independent monitoring raised further doubts, necessitating independent scrutiny before clinical application.
Categories
Anti Cancer cancer research Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment & Outcomes Cancer Treratments Cancer Wellness Protocols Community Impact Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study Integrative Oncology Insights Ivermectin Mebendazole Non-Chemo Cancer Treatments preclinical trial Research & Science
Why did Anticancer Research publish an expression of concern about the 2026 ivermectin study on June 1, 2026?
